Avant Technologies Reaches Global Development and Licensing Deal with Partner, Ainnova Tech, Ahead of FDA Meetings
Avant Technologies Inc. (OTCQB:AVAI) and its partner Ainnova Tech have expanded their joint venture agreement to include a global license for developing and marketing Ainnova's technology portfolio. The partnership, through Ai-nova Acquisition Corp. (AAC), will focus on advancing Ainnova's Vision AI platform and proprietary retinal camera technology.
The Vision AI platform can detect diabetic retinopathy and other retinal diseases, as well as non-retinal conditions like cardiovascular disease, prediabetes, type 2 diabetes, fatty liver diseases, and chronic kidney disease using retinal scans. Under the amended agreement, AAC will have global SaaS and hardware commercialization opportunities with opticians and eye care centers.
This expansion comes ahead of Ainnova's meetings with the FDA to prepare for a planned clinical trial of its Vision AI platform. Ainnova will request a pre-submission meeting for guidance on clinical testing for diabetic retinopathy detection, leading to an FDA 510(k) submission. For Avant, these FDA interactions will help define the budget for the regulatory process and are important for marketing the technology in the United States.
Avant Technologies Inc. (OTCQB:AVAI) e il suo partner Ainnova Tech hanno ampliato il loro accordo di joint venture per includere una licenza globale per lo sviluppo e la commercializzazione del portafoglio tecnologico di Ainnova. La partnership, attraverso Ai-nova Acquisition Corp. (AAC), si concentrerà sullo sviluppo della piattaforma Vision AI di Ainnova e della tecnologia proprietaria della fotocamera retinica.
La piattaforma Vision AI è in grado di rilevare la retinopatia diabetica e altre malattie retiniche, così come condizioni non retiniche come le malattie cardiovascolari, il prediabete, il diabete di tipo 2, le malattie del fegato grasso e le malattie renali croniche utilizzando scansioni retiniche. In base all'accordo modificato, AAC avrà opportunità di commercializzazione globale SaaS e hardware con ottici e centri di cura degli occhi.
Questa espansione avviene in vista degli incontri di Ainnova con la FDA per prepararsi a un trial clinico pianificato della sua piattaforma Vision AI. Ainnova richiederà un incontro di pre-sottomissione per ricevere indicazioni sui test clinici per la rilevazione della retinopatia diabetica, portando a una sottomissione FDA 510(k). Per Avant, queste interazioni con la FDA aiuteranno a definire il budget per il processo normativo e sono importanti per commercializzare la tecnologia negli Stati Uniti.
Avant Technologies Inc. (OTCQB:AVAI) y su socio Ainnova Tech han ampliado su acuerdo de empresa conjunta para incluir una licencia global para el desarrollo y comercialización del portafolio tecnológico de Ainnova. La asociación, a través de Ai-nova Acquisition Corp. (AAC), se centrará en avanzar en la plataforma Vision AI de Ainnova y en la tecnología de cámara retinal propietaria.
La plataforma Vision AI puede detectar retinopatía diabética y otras enfermedades retinianas, así como condiciones no retinianas como enfermedades cardiovasculares, prediabetes, diabetes tipo 2, enfermedades del hígado graso y enfermedad renal crónica utilizando escaneos retinianos. Según el acuerdo modificado, AAC tendrá oportunidades de comercialización global de SaaS y hardware con ópticos y centros de cuidado ocular.
Esta expansión se produce antes de las reuniones de Ainnova con la FDA para prepararse para un ensayo clínico planificado de su plataforma Vision AI. Ainnova solicitará una reunión de pre-sumisión para recibir orientación sobre las pruebas clínicas para la detección de retinopatía diabética, lo que llevará a una presentación FDA 510(k). Para Avant, estas interacciones con la FDA ayudarán a definir el presupuesto para el proceso regulatorio y son importantes para comercializar la tecnología en los Estados Unidos.
Avant Technologies Inc. (OTCQB:AVAI)와 그 파트너 Ainnova Tech는 Ainnova의 기술 포트폴리오 개발 및 마케팅을 위한 글로벌 라이센스를 포함하도록 공동 투자 계약을 확대했습니다. 이 파트너십은 Ai-nova Acquisition Corp. (AAC)를 통해 Ainnova의 Vision AI 플랫폼과 독점 망막 카메라 기술을 발전시키는 데 집중할 것입니다.
Vision AI 플랫폼은 당뇨병성 망막병증 및 기타 망막 질환, 그리고 심혈관 질환, 당뇨 전 단계, 제2형 당뇨병, 지방간 질환 및 만성 신장 질환과 같은 비망막 질환을 망막 스캔을 사용하여 감지할 수 있습니다. 수정된 계약에 따라 AAC는 안경사 및 안과 병원과 함께 글로벌 SaaS 및 하드웨어 상업화 기회를 갖게 됩니다.
이번 확장은 Ainnova의 FDA와의 회의에 앞서 이루어지며, Vision AI 플랫폼의 계획된 임상 시험을 준비하고 있습니다. Ainnova는 당뇨병성 망막병증 감지를 위한 임상 시험에 대한 지침을 요청하기 위해 사전 제출 회의를 요청할 것이며, 이는 FDA 510(k) 제출로 이어질 것입니다. Avant에게 이러한 FDA와의 상호작용은 규제 프로세스의 예산을 정의하는 데 도움이 되며, 미국에서 기술을 마케팅하는 데 중요합니다.
Avant Technologies Inc. (OTCQB:AVAI) et son partenaire Ainnova Tech ont élargi leur accord de coentreprise pour inclure une licence mondiale pour le développement et la commercialisation du portefeuille technologique d'Ainnova. Le partenariat, via Ai-nova Acquisition Corp. (AAC), se concentrera sur l'avancement de la plateforme Vision AI d'Ainnova et de sa technologie de caméra rétinienne propriétaire.
La plateforme Vision AI peut détecter la rétinopathie diabétique et d'autres maladies rétiniennes, ainsi que des conditions non rétiniennes telles que les maladies cardiovasculaires, le prédiabète, le diabète de type 2, les maladies du foie gras et les maladies rénales chroniques à l'aide de scans rétiniens. En vertu de l'accord modifié, AAC disposera d'opportunités de commercialisation mondiale SaaS et matériel avec des opticiens et des centres de soins oculaires.
Cette expansion intervient avant les réunions d'Ainnova avec la FDA pour se préparer à un essai clinique prévu de sa plateforme Vision AI. Ainnova demandera une réunion de pré-soumission pour obtenir des conseils sur les tests cliniques pour la détection de la rétinopathie diabétique, ce qui conduira à une soumission FDA 510(k). Pour Avant, ces interactions avec la FDA aideront à définir le budget pour le processus réglementaire et sont importantes pour commercialiser la technologie aux États-Unis.
Avant Technologies Inc. (OTCQB:AVAI) und sein Partner Ainnova Tech haben ihre Joint-Venture-Vereinbarung erweitert, um eine globale Lizenz zur Entwicklung und Vermarktung des Technologieportfolios von Ainnova einzuschließen. Die Partnerschaft, über Ai-nova Acquisition Corp. (AAC), wird sich darauf konzentrieren, Ainnovas Vision AI-Plattform und proprietäre Netzhauskameratechnologie voranzutreiben.
Die Vision AI-Plattform kann diabetische Retinopathie und andere Netzhauterkrankungen sowie nicht-retinale Erkrankungen wie Herz-Kreislauf-Erkrankungen, Prädiabetes, Typ-2-Diabetes, Fettlebererkrankungen und chronische Nierenerkrankungen mithilfe von Netzhauscans erkennen. Gemäß der geänderten Vereinbarung wird AAC globale SaaS- und Hardware-Kommerzialisierungsmöglichkeiten mit Optikern und Augenpflegezentren haben.
Diese Expansion erfolgt vor Ainnovas Treffen mit der FDA, um sich auf eine geplante klinische Studie ihrer Vision AI-Plattform vorzubereiten. Ainnova wird ein Pre-Submission-Meeting anfordern, um Anleitung zu klinischen Tests zur Erkennung von diabetischer Retinopathie zu erhalten, was zu einer FDA 510(k)-Einreichung führen wird. Für Avant werden diese Interaktionen mit der FDA dazu beitragen, das Budget für den regulatorischen Prozess zu definieren, und sind wichtig für die Vermarktung der Technologie in den Vereinigten Staaten.
- Global expansion of licensing territory for joint venture
- Technology can detect multiple diseases beyond retinal conditions
- Preparing for FDA clinical trials and 510(k) submission
- SaaS + hardware commercialization model with eye care centers
- FDA approval still pending with uncertain timeline
- Clinical trial costs and budget not yet defined
- Success dependent on FDA interactions and clearance
LAS VEGAS, NV / ACCESS Newswire / February 25, 2025 / Avant Technologies Inc. (OTCQB:AVAI) ("Avant" or the "Company"), and its partner, Ainnova Tech, Inc., (Ainnova), a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI), today announced that the companies have agreed to expand the territory for Ai-nova Acquisition Corp. (AAC), the joint venture formed by both companies. In an addendum to the December 2024 Joint Venture Agreement between Avant and Ainnova, AAC's territory now includes a global license to develop and market Ainnova's "technology portfolio."
The partnership was formed to advance and commercialize Ainnova's portfolio, including its Vision AI platform and its proprietary versatile retinal camera technology. Vision AI is a cutting-edge, AI-driven platform that can detect diabetic retinopathy and other retinal diseases, as well as diseases unrelated to the retina like cardiovascular disease, prediabetes and type 2 diabetes, fatty liver diseases, and chronic kidney disease with high accuracy and speed using retinal scans. Meanwhile, Ainnova's next-generation versatile retinal cameras are seamlessly integrated with Vision AI for precise retinal scans.
Under the amended agreement, Ainnova's Vision AI software, combined with its retinal cameras, will offer AAC SaaS + retinal camera commercialization opportunities with opticians and eye care centers worldwide.
Avant has broadened its territory, through the joint venture, ahead of Ainnova's meetings with the U.S. Food and Drug Administration (FDA) to prepare for a planned FDA clinical trial with its Vision AI platform. Ainnova will begin by requesting a pre-submission meeting with the FDA for guidance on the clinical testing needed for its Vision AI platform in the early detection of diabetic retinopathy, which will culminate with an FDA 510(k) submission to obtain clearance from the FDA to market its technology.
For Avant, the presubmission meeting will help define a precise budget for the strategic partnership's entire FDA process, and the success of Ainnova's interactions with the FDA are paramount to AAC marketing the technology portfolio in the United States.
About Ainnova Tech, Inc.
Ainnova is a Nevada-based healthtech startup with headquarters in San Jose, Costa Rica, and Houston, Texas. Founded by an experienced and innovative team that is dedicated to leveraging artificial intelligence for early disease detection. Recognized with multiple global awards and renowned partnerships with hospitals and medical device companies, we proudly introduce VisionAI - our cutting-edge platform designed to prevent blindness and detect the early onset of diabetes. Explore how Ainnova is revolutionizing healthcare through advanced technology and proactive solutions.
About Avant Technologies, Inc.
Avant Technologies Inc. is an emerging technology company developing solutions in artificial intelligence in healthcare. With a focus on pushing the boundaries of what is possible in AI and machine learning, Avant serves a diverse range of industries, driving progress and efficiency through state-of-the-art technology.
More information about Avant can be found at https://avanttechnologies.com
You can also follow us on social media at:
https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant-technologies-ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company's ability to raise capital on acceptable terms, if at all, the Company's successful development of its products and the integration into its existing products and the commercial acceptance of the Company's products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.
Contact:
Avant Technologies, Inc.
info@avanttechnologies.com
SOURCE: Avant Technologies
View the original press release on ACCESS Newswire
FAQ
What is the expanded territory in Avant Technologies' (AVAI) deal with Ainnova Tech?
What medical conditions can Ainnova's Vision AI platform detect according to AVAI's announcement?
What regulatory steps is AVAI's partner Ainnova taking with the FDA?
How will AVAI benefit from Ainnova's FDA meetings?
What commercial opportunities does the AVAI-Ainnova joint venture now have globally?
